Brief: Crossject Announces FDA Attributed To Zeneo Midazolam The Oprhan Drug Status

Crossject SA

02/02/2018 07:55

Feb 2 (Reuters) - Crossject SA  ALCJ.PA : 
    * ANNOUNCED ON THURSDAY THAT FDA ATTRIBUTED TO ZENEO 
MIDAZOLAM THE 
OPRHAN DRUG STATUS  
    * CROSSJECT CONFIRMS THE OBJECTIVE OF RA SUBMISSION FOR 
ZENEO 
MIDAZOLAM IN 2019, IN THE USA AND IN EUROPE 
 
     
 Source text for Eikon:  urn:newsml:reuters.com:*:nGNE2gyfZM 
     
 Further company coverage:  ALCJ.PA   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))